{"schema_version":"secwatch.filing_event.v1","accession":"0001274737-24-000045","form_type":"8-K","ticker":"XGN","cik":"0001274737","company_name":"EXAGEN INC.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.672190+00:00","generated_at":"2026-06-02T01:58:41.017673+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Exagen Q1 revenue up 28% to $14.4M; raises FY2024 guidance","bullets":["Revenue $14.4M, +28.4% YoY; gross margin 59.6% vs 47.2% a year ago.","Net loss $3.4M, a 56.3% improvement; adjusted EBITDA -$2.0M, a 67.7% improvement.","AVISE CTD trailing 12-month ASP $377, up 35.1% versus prior year.","Company raises full-year 2024 revenue and adjusted EBITDA guidance on strong momentum.","Cash and equivalents $27.3M; accounts receivable $10.9M; cash runway into 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001274737-24-000045","json":"https://secwatch.observer/filing/0001274737-24-000045.json","markdown":"https://secwatch.observer/filing/0001274737-24-000045.md","text":"https://secwatch.observer/filing/0001274737-24-000045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1274737/000127473724000045/0001274737-24-000045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1274737/000127473724000045/exdx-20240513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:58:41.017673+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1595ad02ae5cd2c6187285d56d20907e682fcfba","claim":"EXAGEN INC. reported the quarter ended March 31, 2024 results: revenue $14.4 million, net income $3.4 million. Guidance raised.","evidence_excerpt":"leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2024. First Quarter Highlights: • Recognized total revenue of $14.4 million in the first quarter of 2024, a 28.4% increase over the first quarter of 2023. • Delivered gross margin of 59.6% in the first quarter of 2024, compared to a gross margin of 47.2%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1274737/000127473724000045/0001274737-24-000045-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$14.4 million"},{"label":"Net income","value":"$3.4 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}